Immunobiology of inhibitor development in hemophilia A.
After treatment with factor (F) VIII concentrate a significant number of patients with hemophilia A develop inhibitory antibodies that neutralize FVIII. Epitope mapping revealed that antibodies bind to selected regions within the A2, A3, and C2 domains of FVIII. Anti-A2 and anti-A3 antibodies interfere with assembly of FVIIIa with FIXa, whereas anti-C2 antibodies impede the interaction of FVIII with phospholipids. The immunologic mechanisms underlying inhibitor development in hemophilia A have not been fully elucidated. FVIII is recognized by the immune system as a foreign antigenic substance that evokes the T cell-dependent formation of high-affinity antibodies. Clonal analysis of B cell responses in hemophilia A patients has given further insight into the epitope specificity and molecular characteristics of FVIII inhibitors. Costimulatory blockade of FVIII-reactive T cells in a mouse model for hemophilia A has suggested new approaches for treatment of inhibitor patients. In this article, recent studies on the immunobiology of FVIII inhibitors are summarized and discussed with reference to their potential impact on treatment and prevention of immune responses in patients with hemophilia.
Fijnvandraat
Karin
K
Department of Pediatrics, Emma Children's Hospital, Academic Medical Center, University of Amsterdam, The Netherlands.
Bril
Wendy S
WS
Voorberg
Jan
J
D001402:B-Lymphocytes / Q000276:immunology; D018604:Epitope Mapping; D005169:Factor VIII / Q000737:chemistry* / Q000276:immunology; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D008954:Models, Biological; D008958:Models, Molecular; D017434:Protein Structure, Tertiary; D013601:T-Lymphocytes / Q000378:metabolism; D013997:Time Factors
D005169:Factor VIII